The Accuracy of Mammogram and Ultrasound in Assessment of Tumour Size and Lymph Node Involvement in Invasive Breast Cancer

2020 ◽  
Vol 27 (2) ◽  
pp. 27-35
Author(s):  
Harahsheh , Hend M. ◽  
Al-Bdour , Bilal A. ◽  
Ayyad , Rawan M. ◽  
Al-Habahbeh , Laith M. ◽  
AL Waqfi , Ola M.
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Invasive Breast Cancer ◽  
Tumour Size ◽  
Lymph Node Involvement ◽  
Node Involvement

A Prediction Model for the Presence of Axillary Lymph Node Involvement in Women with Invasive Breast Cancer: A Focus on Older Women

2014 ◽  
Vol 20 (2) ◽  
pp. 147-153 ◽  
Author(s):  
Lauren T. Greer ◽  
Martin Rosman ◽  
W. Charles Mylander ◽  
Wen Liang ◽  
Robert R. Buras ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Prediction Model ◽  
Older Women ◽  
Invasive Breast Cancer ◽  
Axillary Lymph Node ◽  
Lymph Node Involvement ◽  
Axillary Lymph ◽  
Node Involvement ◽  
Axillary Lymph Node Involvement

scholarly journals Predictive Value of Tumor Load in Breast Cancer Sentinel Lymph Nodes for Second Echelon Lymph Node Metastases

2007 ◽  
Vol 29 (6) ◽  
pp. 497-505
Author(s):  
C. H. M. van Deurzen ◽  
R. van Hillegersberg ◽  
M. G. G. Hobbelink ◽  
C. A. Seldenrijk ◽  
R. Koelemij ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Invasive Breast Cancer ◽  
Primary Tumor ◽  
Lymph Node Involvement ◽  
Consecutive Series ◽  
Axillary Lymph ◽  
Tumor Load ◽  
Node Involvement

Background: The need for routine axillary lymph node dissection (ALND) in patients with invasive breast cancer and low-volume sentinel node (SN) involvement is questionable. Accurate prediction of second echelon lymph node involvement could identify those patients most likely to benefit from ALND.Methods: A consecutive series of 317 patients with invasive breast cancer and a tumor positive axillary SN followed by ALND was reviewed. Clinicopathologic features of the primary tumor and the SN were assessed as possible predictors of second echelon lymph node involvement.Results: Second echelon metastases were found in 116/317 cases (36.6%). Frequency of second echelon lymph node involvement in patients with isolated tumor cells (ITC, N = 23), micro- (N = 101) and macrometastases (N = 193) was 13%, 20% and 48%, respectively (p < 0.001). Based on the area % of SN occupied by tumor no subgroup of patients could be selected with less than 20% second echelon lymph node involvement. However, none of the patients with SN ITC or micrometastases and a primary tumor size ≤1 cm (N = 12, 3.8%) had second echelon lymph node involvement.Conclusions: Accurately measured SN tumor load predicts second echelon lymph node involvement. However, even in patients with ITC, the second echelon lymph nodes are involved in 13% justifying ALND.

Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement

2007 ◽  
Vol 106 (3) ◽  
pp. 433-438 ◽  
Author(s):  
Kyoung-Mu Lee ◽  
Ji-Yeob Choi ◽  
Jong Eun Lee ◽  
Dong-Young Noh ◽  
Sei-Hyun Ahn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Genetic Polymorphisms ◽  
Invasive Breast Cancer ◽  
Lymph Node Involvement ◽  
Node Involvement

Risk stratification by hormonal receptor (ER, PgR) and HER2 status in small (≤1cm) invasive breast cancer: Who might be a possible candidate for adjuvant treatment?

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 564-564
Author(s):  
Y. Park ◽  
S. Kim ◽  
O. Ok ◽  
H. Baek ◽  
J. Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Invasive Breast Cancer ◽  
Axillary Lymph Node ◽  
Lymph Node Involvement ◽  
Axillary Lymph ◽  
Positive Group ◽  
Node Involvement ◽  
Her 2 ◽  
Axillary Lymph Node Involvement

564 Background: With the increasing use of screening mammography, the proportion of ≤ 1 cm invasive breast cancer is increasing. Identification of breast cancer molecular subtypes has resulted in a better appreciation of the biologic heterogeneity, which is not fully explained by clinicopathologic features including staging system. The aims of this study were: 1) to identify the risk factors of systemic metastases in patients with ≤ 1 cm invasive breast cancer and 2) to investigate the patients group at greatest risk of such failure even in these small tumors. Method: Data were collected retrospectively in the breast cancer registry of our institution for patients with invasive breast cancer from October 1994 to December 2004. Results: Of 4,036 patients who received curative breast cancer surgery, 466 patients who had T1a or T1b breast cancer were identified. 39 patients who received neoadjuvant chemotherapy were excluded in this study. Ipsilateral axillary lymph node involvement was found in 13% (57/427) at the time of surgery. Axillary lymph node involvement was much more common in HER-2 positive group (33% vs 11%, p < 0.0001) and triple negative (TN) group (24% vs 11%, p = 0.002) than in hormone receptor positive group. During median 61 months of follow-up, overall 10 year estimated distant relapse-free survival (DRFS) and overall survival (OS) were 95% and 92%, respectively. Multivariate analysis was conducted in 370 (T1aN0, T1bN0) patients, who had no lymph node involvement. In Cox-regression model, HER-2 positivity and triple negativity were identified as independent prognostic factors to predict DRFS [Hazard ratio (HR) 8.8, p = 0.003 for HER-2 positive group; HR 5.1, p = 0.026 for TN group] and OS (HR 5.0, p = 0.067 for HER-2 positive group; HR 11.1, p = 0.017 for TN group) in T1bN0 tumors. Limiting to T1aN0 tumors, statistical significance was not maintained. Conclusions: Even though T1aN0 and T1bN0 tumors have been known to have a relative low risk of systemic failure, anti-HER-2 directed therapy for HER-2 positive group and new innovative adjuvant systemic treatment for TN group in patients with T1bN0 tumor should be considered. Prospective adjuvant trials should be warranted in these subgroups of patients. No significant financial relationships to disclose.

scholarly journals Correlation of plasma D-dimer levels with breast carcinoma

2021 ◽  
Vol 8 (12) ◽  
pp. 3622
Author(s):  
Amruthavarshini Satish Halugodu ◽  
Vidhyasagar M. Sharma
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymphovascular Invasion ◽  
Histopathological Examination ◽  
Histological Grade ◽  
Tumour Size ◽  
Lymph Node Involvement ◽  
Advanced Stage ◽  
Node Involvement ◽  
D Dimer

Background: Breast cancer is the most commonly occurring cancer in women. There is a correlation between cancer and hyper coagulation. Carcinoma increases the level of cross-linked fibrin degradation product (plasma D-dimer), indicative of systemic activation of fibrinolysis, hemostasis and angiogenesis. This study attempted to correlate raised plasma D-dimer in breast cancer.Methods: A retrospective study was conducted in the department of general surgery in GCS hospital, Ahmedabad where in patients admitted and treated for breast cancer between July 2020 to June 2021 were selected. Plasma D-dimer levels were correlated with final histopathological examination of breast specimen.Results: Plasma D-dimer levels were increased with advancing stage of disease, lymph node involvement and lymphovascular invasion. There was no significant relationship with increase in tumour size and histopathological grade of tumour.Conclusions: Plasma D-dimer levels are elevated in breast cancer, especially with advanced stage. It is an important marker of clinical stage, lymphovascular invasion, lymph node involvement. However it does not correlate with tumour size and histological grade. So pre- operative plasma D-dimer level is a safe, cost effective and convenient method for prediction of advanced stage in breast cancer.

scholarly journals Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies

2004 ◽  
Vol 15 (11) ◽  
pp. 1633-1639 ◽  
Author(s):  
M. Colleoni ◽  
N. Rotmensz ◽  
G. Peruzzotti ◽  
P. Maisonneuve ◽  
G. Viale ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Invasive Breast Cancer ◽  
Axillary Lymph Node ◽  
Lymph Node Involvement ◽  
Axillary Lymph ◽  
Adjuvant Therapies ◽  
Node Involvement ◽  
Axillary Lymph Node Involvement
Sign in / Sign up

Export Citation Format

Share Document